{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:49:59Z","timestamp":1791823799528,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.seizure.2021.02.010","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T10:35:15Z","timestamp":1613385315000},"page":"138-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Long-term seizure outcome and antiseizure medication use in autoimmune encephalitis"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2322-6534","authenticated-orcid":false,"given":"Maria","family":"Ilyas-Feldmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Pr\u00fc\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Holtkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2021.02.010_bib0005","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/epi.16571","article-title":"Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions","volume":"61","author":"Steriade","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.02.010_bib0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ana.21917","article-title":"Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis","volume":"67","author":"Malter","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2021.02.010_bib0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.seizure.2020.07.019","article-title":"Seizures and epilepsy of autoimmune origin: a long-term prospective study","volume":"81","author":"Falip","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.02.010_bib0020","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/brain\/awh203","article-title":"Clinical analysis of anti-Ma2-associated encephalitis","volume":"127","author":"Dalmau","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.seizure.2021.02.010_bib0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1474-4422(13)70260-6","article-title":"Rasmussen\u2019s encephalitis: clinical features, pathobiology, and treatment advances","volume":"13","author":"Varadkar","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2021.02.010_bib0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/epi4.12226","article-title":"Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine-rich glioma-inactivated protein 1","volume":"3","author":"Feyissa","year":"2018","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2021.02.010_bib0035","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/brain\/awx323","article-title":"The importance of early immunotherapy in patients with faciobrachial dystonic seizures","volume":"141","author":"Thompson","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.seizure.2021.02.010_bib0040","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.02.010_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577268","article-title":"LGI1-antibody associated epilepsy successfully treated in the outpatient setting","volume":"345","author":"Uribe-San-Mart\u00edn","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.seizure.2021.02.010_bib0050","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/epi.13929","article-title":"Seizure outcomes in patients with anti-NMDAR encephalitis: a follow-up study","volume":"58","author":"Liu","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.02.010_bib0055","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fneur.2018.00579","article-title":"Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: the interplay between immunotherapy and anti-epileptic drugs","volume":"9","author":"M\u00e4kel\u00e4","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2021.02.010_bib0060","doi-asserted-by":"crossref","first-page":"e2185","DOI":"10.1212\/WNL.0000000000007475","article-title":"Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA(B)R encephalitis","volume":"92","author":"de Bruijn","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.02.010_bib0065","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/acn3.51137","article-title":"Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABA(B) R encephalitis","volume":"7","author":"Shen","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.seizure.2021.02.010_bib0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jocn.2019.07.049","article-title":"Clinical features and long-term outcomes of seizures associated with autoimmune encephalitis: a follow-up study in East China","volume":"68","author":"Yao","year":"2019","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.seizure.2021.02.010_bib0075","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1212\/NXI.0000000000000353","article-title":"Antiepileptic drug therapy in patients with autoimmune epilepsy","volume":"4","author":"Feyissa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.seizure.2021.02.010_bib0080","article-title":"Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data","author":"Rada","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.seizure.2021.02.010_bib0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.yebeh.2018.10.038","article-title":"Seizure characteristics, treatment, and outcome in autoimmune synaptic encephalitis: a long-term study","volume":"94","author":"Zhang","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2021.02.010_bib0090","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2021.02.010_bib0095","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.02.010_bib0100","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.02.010_bib0105","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.02.010_bib0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.seizure.2015.05.017","article-title":"Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies","volume":"30","author":"Malter","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.02.010_bib0115","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1212\/WNL.0000000000000383","article-title":"Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy","volume":"82","author":"Toledano","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.02.010_bib0120","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s00415-020-09814-3","article-title":"Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome","volume":"267","author":"Bien","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.seizure.2021.02.010_bib0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fpsyt.2017.00025","article-title":"Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients","volume":"8","author":"Herken","year":"2017","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.seizure.2021.02.010_bib0130","first-page":"526","article-title":"Limbic encephalitis: the new cell membrane antigens and a proposal of clinical-immunological classification with therapeutic implications","volume":"22","author":"Dalmau","year":"2007","journal-title":"Neurologia"},{"key":"10.1016\/j.seizure.2021.02.010_bib0135","doi-asserted-by":"crossref","unstructured":"England MJ, Liverman CT, Schultz AM, Strawbridge LM, editors. Epilepsy Across the Spectrum: Promoting Health and Understanding. Washington (DC): 2012. https:\/\/doi.org\/10.17226\/13379.","DOI":"10.17226\/13379"},{"key":"10.1016\/j.seizure.2021.02.010_bib0140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaneurol.2016.4226","article-title":"Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies","volume":"74","author":"Finke","year":"2017","journal-title":"JAMA Neurol"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121000443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121000443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:59:16Z","timestamp":1761011956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121000443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":28,"alternative-id":["S1059131121000443"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.02.010","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term seizure outcome and antiseizure medication use in autoimmune encephalitis","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}